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Response to ‘Autophagy: a
protective mechanism against
nephrotoxicant-induced renal
injury’
Kidney International (2009) 75, 119; doi:10.1038/ki.2008.540
We thank Dr. Pallet and Dr. Anglicheau for their interest in
our recent publication reporting autophagy in cisplatin
nephrotoxicity and its cytoprotective role.1 We are pleased
to learn that their latest work has also demonstrated
autophagy as a protective mechanism against cyclosporine
toxicity in renal cells and tissues.2 Interestingly, whereas
we showed the regulation of cisplatin-induced autophagy
by p53, BcL-2, and related mechanisms, Pallet et al. further
emphasized the involvement of ER stress in autophagy
during cyclosporine toxicity. Although we did not examine
ER stress in the cisplatin model, we believe this is a
possibility that deserves consideration and further inves-
tigation. As correctly pointed out, cisplatin can induce ER
stress. In this regard, Liu and Baliga3 showed evidence for
ER stress during cisplatin treatment of renal tubular cells.
Nevertheless, multiple stresses and signaling pathways are
induced or activated during cisplatin nephrotoxicity.4
Notably, cisplatin induces pathological alterations in
several subcellular sites or organelles including mitochon-
dria, ER, and the nucleus. As a result, cellular responses,
either cytoprotective or injurious, may be mediated by
multiple rather than a single mechanism.4 Certainly, a
specific stress or pathway may have a major role in the
induction of autophagy; whether it is ER stress remains to
be determined. In addition, the signaling pathways
activated by cisplatin may also cross talk and be integrated,
resulting in an impressive renal pathology. The recent
studies by this and other laboratories have suggested that
autophagy is a renoprotective mechanism during cisplatin
and cyclosporine nephrotoxicity.1,2,5 However, whether
this conclusion can be generalized to other kidney injury
models (for example renal ischemia-reperfusion) remains
to be investigated, as excessive autophagy can lead to cell
death. Thus we have to agree with Dr. Lieberthal that ‘the
extent to which autophagy can ameliorate kidney injury
caused by other types of renal insults remains to be
determined’.6 It is hoped that these studies have provided
impetus for investigation of autophagy in renal patho-
physiology.
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Telmisartan is more effective than
losartan in reducing proteinuria
Kidney International (2009) 75, 119–120; doi:10.1038/ki.2008.538
To the Editor: We read with interest the paper that
Telmisartan is more effective than losartan in reducing
proteinuria in patients with Diabetic Nephropathy recently
published in Kidney International by Bakris et al.1 where the
effects of telmisartan 80 mg was compared with losartan
100 mg in 860 patients with type 2 diabetes treated for 52
weeks. The authors showed that with telmisartan, proteinuria
decreased from 1.42 to 0.95 g per g creatinine (Po0.0001)
and with losartan, proteinuria decreased from 1.39 to 1.05 g
per g creatinine (Po0.0001) at the end of the study. They
also documented a trend in favor of telmisartan where there
was a difference of 4.2 mm Hg difference in systolic blood
pressure compared to losartan. We would like to comment on
the dose of telmisartan and losartan used in Bakri’s study.
From our observation, comparing telmisartan 80 mg with
losartan 100 mg would favor telmisartan with regards to
clinical efficacy in particular with respect to reduction of
proteinuria.
We would like to share our own experience in a clinical
trial involving patients with IgA nephritis treated with
losartan 100 mg (n¼ 45) compared to those treated with
losartan 200 mg (n¼ 61) over a 6-year period from 2001 to
2007.2 In the losartan 100 mg group, proteinuria decreased
from 2.1±1.0 to 1.7±1.0 g/day compared to losartan 200 mg
group where proteinuria decreased from 2.1±0.8 to
Kidney International (2009) 75, 115–121 119
l e t t e r t o t h e e d i t o r
1.0±0.8 g/day (Po0.001). There was no significant differ-
ence in the systolic blood pressure between the two groups
before and after the study (P¼ 0.447). Neither was there a
difference in the diastolic blood pressure (P¼ 0.159). The
decrease in the estimated glomerular filtration rate (eGFR)
was 3.5 ml/min/year for the losartan 100 mg group compared
to 0.7 ml/min/year for the losartan 200 mg group
(Po0.0005) and there were significantly less patients with
chronic kidney disease (CKD) 4 and 5 in the losartan 200 mg
group compared to the 100 mg group (Po0.005) at the end
of 6 years.
From our experience, dose for dose, losartan is probably
equipotent to telmisartan, that is if prescribed in the dose of
losartan 150 mg versus telmisartan 80 mg. Telmisartan,
because of its longer half-life in terms of blood pressure
control3 has the advantage of offering better renoprotection
in hypertensive CKD patients (whether diabetic or IgA
nephropathy). But for patients who do not have hypertension
associated with CKD, losartan may be more appropriate as it
is a relatively weaker hypotensive drug4 and one can prescribe
larger doses without the side effects of giddiness and
hypotension. In the long term, what is of paramount
importance is preservation of renal function and prevention
of renal failure. In this respect, data for telmisartan 80 mg5
and our own studies on losartan 200 mg2 have shown that
after 5 years therapy there is a gain in eGFR for both of these
drugs which has yet to be demonstrated by other angio-
tension receptor blocker (ARBs) or angiotension converting
enzyme inhibitor (ACEI).
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We read with interest your letter in response to our trial.
We very much appreciate the issue of dose equivalence
between losartan and telmisartan. There are clearly
differences between these two agents with regard to AT1
receptor binding at the doses we used.1,2 The doses
selected, however, resulted from those most commonly
used in the United States. They are also the maximum
approved doses by the Food and Drug Administration. The
dose escalation of losartan and results on proteinuria
reduction mirror those seen with other angiotensin
receptor blocker (ARBs). Dose escalation studies with
candesartan have also shown similar findings on protei-
nuria without substantial additional blood pressure
reductions.3,4 Thus, we appreciate your observations and
do not find them surprising. It is clear that increasing ARB
dose above the current guideline recommendations to
reduce proteinuria further is warranted; this should also
be considered by regulatory agencies. The one interesting
finding in the study was that the decline in estimated
glomerular filtration rate (eGFR) was less at the higher
dose. This is important and needs confirmation in longer-
term studies.
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Adiponectin in chronic kidney
disease: Dr Jekyll and Mr Hyde
Kidney International (2009) 75, 120–121; doi:10.1038/ki.2008.541
To the Editor: We read with interest the commentary by
Costacou and Orchard1 on the hypothesis that elevated
adiponectin levels may occur as a protective response to
vascular damage. Although such changes may be operative in
CKD, we believe that the putative involvement of adiponectin
in the process of protein-energy wasting also needs
consideration. As adiponectin is produced in inverse
proportion to fat mass, wasted patients who have lost body
weight would, as a consequence, have higher plasma
adiponectin values.2 Thus, it is not unexpected that
adjustment for body mass index resulted in the loss of
impact on mortality by adiponectin in patients with chronic
heart failure.3 Also, a nested case–control study showed that
adiponectin reflects the degree of systemic wasting that
precedes death.4 On the other hand, as intracerebroventri-
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